Oct 31 (Reuters) - AbbVie ( ABBV ) raised its 2025

profit forecast on Friday, after strong sales of newer

immunology drugs Skyrizi and Rinvoq helped boost third-quarter

results above Wall Street estimates.

The North Chicago-based drugmaker has been leaning on

Skyrizi and Rinvoq to offset declining sales of its once

best-selling arthritis treatment Humira that began facing

biosimilar competition in the U.S. in 2023.

The company has poured more than $20 billion into

acquisitions since then, and plans to spend another $10 billion

on expanding within the United States over the next decade.

Global pharmaceutical companies are bolstering their U.S.

manufacturing capacity after President Donald Trump urged the

industry to make more medicines domestically rather than

importing active ingredients or finished medicines.

AbbVie ( ABBV ) now expects adjusted annual profit per share of

between $10.61 and $10.65, compared with its previous

expectations of $10.38 to $10.58.

Its quarterly sales of $15.78 billion beat analysts' average

estimate of $15.59 billion, according to data compiled by LSEG.

Global sales of AbbVie's ( ABBV ) flagship arthritis treatment Humira

came in at $993 million in the third quarter, missing estimates

of $1.15 billion, and marking the first time the drug's sales

have dropped below $1 billion since it lost exclusivity.

During the quarter, Skyrizi brought in sales of $4.71

billion, surpassing estimates of $4.44 billion, while Rinvoq

sales of $2.18 billion topped estimates of $2.12 billion.

The drugmaker earned quarterly profit per share of $1.86,

above estimates of $1.77 per share.

AbbVie ( ABBV ) said the quarterly results include an unfavorable

impact of $1.50 per share related to acquired in-process

research and development expenses, announced earlier this month.

(Reporting by Siddhi Mahatole and Puyaan Singh in Bengaluru;

Editing by Devika Syamnath)